Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Clinical evidence

HELP

14 evidence topics · 3 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Subcutaneous lanadelumab regimens; placebo comparator
RegimenDose and interval
Lower-dose monthly“150 mg q4wks”
Higher-dose monthly“300 mg q4wks”
Every two weeks“300 mg q2wks”
Study outcomes
Rationale for using monthly HAE attack rate as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized treatment groups
GroupParticipants
Lanadelumab 150 mg every four weeks“28”
Lanadelumab 300 mg every four weeks“29”
Lanadelumab 300 mg every two weeks“27”
Placebo“41”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Age at baseline
Efficacy results
Mean monthly attack rate over 26 weeks
TreatmentAttacks per month
Lanadelumab 150 mg every four weeks“0.48”View highlighted excerpt for this quote
Lanadelumab 300 mg every four weeks“0.53”View highlighted excerpt for this quote
Lanadelumab 300 mg every two weeks“0.26”View highlighted excerpt for this quote
Placebo“1.97”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Participants achieving the AE-QoL minimal clinically important difference
PopulationProportion
All lanadelumab regimens pooled“70%”
Placebo“37%”
Lanadelumab 300 mg every two weeks“81%”
Safety results
Injection-site reactions
TreatmentParticipants, n (%)
Lanadelumab 150 mg every four weeks, n=28“16 (57)”
Lanadelumab 300 mg every four weeks, n=29“13 (45)”
Lanadelumab 300 mg every two weeks, n=27“15 (56)”
Placebo, n=41“14 (34)”
Study limitations
Summary

The trial randomized 125 participants to three lanadelumab regimens (28, 29, and 27 participants) or placebo (41 participants), and 113 (90.4%) completed the study. The primary analysis used the “Intent-to-Treat” population and a “Poisson regression model”. Because three active regimens shared the randomization, each lanadelumab group contained 27 to 29 participants, which limits precision for comparisons between regimens and for uncommon adverse events; injection-site reactions were reported in 45% to 57% of lanadelumab groups and in 34% of the placebo group. The placebo-controlled period does not describe outcomes over longer treatment. Lanadelumab was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, run-in requirements, baseline attack rates, and observation periods can affect the reported attack rates.